FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesGCSG 2020 Global Virtual Conference Tour
Topic: Conference
Video
Free
COVID-19’s Impact on the Supply Chain in Asia-Pacific
Topics: COVID-19, Supply Chain
Webinar
Free
Why Brexit Happened and What to Do Next
Topic: Politics
TED Talk
Free